{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-097555","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.901554+00:00","generated_at":"2026-05-15T17:55:47.554656+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results","bullets":["Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.","Plans to drop 600mg dose arm in Part B; enroll up to 256 patients (down from 480) to randomize 128 (down from 192).","FY2025 net loss $162.3M ($4.20/share) vs $85.0M ($2.55/share) in FY2024.","Cash $514.4M provides runway into 2028.","Phase 3 gMG trial of claseprubart to start mid-2026; top-line data expected 2H’28."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-097555","json":"https://secwatch.observer/filing/0001193125-26-097555.json","markdown":"https://secwatch.observer/filing/0001193125-26-097555.md","text":"https://secwatch.observer/filing/0001193125-26-097555.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/0001193125-26-097555-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:55:47.554656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e51fc3f60f8a135f76ebfbc113ff07ea3abb9b1c","claim":"Dianthus Therapeutics, Inc. /DE/ reported the fourth quarter and full year ending December 31, 2025 results: net income $162.3 million or $4.20 per share, EPS $4.20 per share.","evidence_excerpt":"On March 9, 2026, Dianthus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and full year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/0001193125-26-097555-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ending December 31, 2025"},{"label":"Net income","value":"$162.3 million or $4.20 per share"},{"label":"EPS","value":"$4.20 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}